Nina Shah, MD, Discusses Key Results of the Phase 2 KarMMa Trial of Ide-Cel in R/R Multiple Myeloma
April 25th 2022At the 2022 Tandem Meetings, Nina Shah, MD, spoke about key findings from the phase 2 KarMMa trial that used idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Peter Humphrey, MD, PhD, Discusses Histology and Clinical Trial Enrollment in RCC
April 25th 2022At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how enrollment for specific trials in renal cell carcinoma may incorporate a patient’s tumor histology.
Daniel P. Petrylak, MD, Reviews Ongoing Clinical Trials in Bladder Cancer
April 22nd 2022At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about ongoing trials may hold promise for the treatment of patients with bladder cancer.